Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226655 · ClinicalTrials.gov registry record · Phase 3
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
A Phase 3 study, sponsored by Celtic Pharma Development Services.
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
NCT00226655 is a Phase 3 study that has completed, run by Celtic Pharma Development Services. The registered enrollment target is 112 participants.
The verdict
NCT00226655, a Phase 3 study, has completed, sponsored by Celtic Pharma Development Services.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other designated studies, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.
Interventions
- DRUG hCRF [XERECEPT (corticorelin acetate injection)]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226655
The ClinicalTrials.gov registry entry for NCT00226655 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celtic Pharma Development Services, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hCRF [XERECEPT (corticorelin acetate injection)] is the first listed.
NCT00226655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226655 about?
NCT00226655 is a clinical study titled "An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies". The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in eit...
What is the current status of trial NCT00226655?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2005-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00226655?
The interventions under investigation include: hCRF [XERECEPT (corticorelin acetate injection)] (DRUG).
Who is sponsoring clinical trial NCT00226655?
This trial is sponsored by Celtic Pharma Development Services, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.